IL13 and Pruritus: In a phase 2b, placebo-controlled, double-blind trial, as early as day 2 in the higher-dosage group, the humanized high-affinity IL-13 antibody lebrikizumab significantly reduced the severity of AD and the intensity of pruritus [101].